R Fellin1, E Manzato2. 1. Department of Internal Medicine, University of Ferrara, Italy. 2. Department of Medicine, University of Padua, Italy. Electronic address: enzo.manzato@unipd.it.
Abstract
AIMS: To review the formation, catabolism, and the possible atherogenic properties of Lp-X. DATA SYNTHESIS: The conversion of cholesterol to bile acids is regulated by several mechanisms including cholesterol 7 alpha hydroxylase, fibroblast growth factor 19, and farnesoid X receptors. During cholestasis these mechanisms are altered and there is an accumulation of bile acids and cholesterol in plasma. The hypercholesterolemia observed in cholestasis is due to the presence of an anomalous lipoprotein called lipoprotein-X (Lp-X). Lp-X is a lipoprotein rich in phospholipid and free cholesterol present in plasma of patients with cholestasis and, with some variations, in patients with lecithin-cholesterol-acyl-transferase deficiency (LCAT), and after lipid infusion. Lp-X is formed from a bile lipoprotein moving to the blood vessels where it incorporates small quantities of triglycerides, apo-C and esterified cholesterol and becomes a "mature" Lp-X. The activity of the phosphatidilcholine canalicular transporter Mdr2 P-glycoprotein (homologous to the human ABCB4) is essential for LpX appearance, since its suppression abolishes Lp-X formation. However, the concentration of Lp-X in plasma is determined also by the degree of the cholestasis, the residual liver function, and the LCAT deficiency. The Lp-X catabolism seems to be mediated by the reticuloendothelial system and possibly the kidney. CONCLUSIONS: Lp-X might be considered a defense mechanism against the toxic effect of free cholesterol in cholestasis. The frequency of cardiovascular events in patients affected by primary biliary cholangitis, in whom the Lp-X is present in high concentration, are not increased. Further studies could now clarify the remaining open questions on the role of Lp-X in the dyslipidemia of cholestasis.
AIMS: To review the formation, catabolism, and the possible atherogenic properties of Lp-X. DATA SYNTHESIS: The conversion of cholesterol to bile acids is regulated by several mechanisms including cholesterol 7 alpha hydroxylase, fibroblast growth factor 19, and farnesoid X receptors. During cholestasis these mechanisms are altered and there is an accumulation of bile acids and cholesterol in plasma. The hypercholesterolemia observed in cholestasis is due to the presence of an anomalous lipoprotein called lipoprotein-X (Lp-X). Lp-X is a lipoprotein rich in phospholipid and free cholesterol present in plasma of patients with cholestasis and, with some variations, in patients with lecithin-cholesterol-acyl-transferase deficiency (LCAT), and after lipid infusion. Lp-X is formed from a bile lipoprotein moving to the blood vessels where it incorporates small quantities of triglycerides, apo-C and esterified cholesterol and becomes a "mature" Lp-X. The activity of the phosphatidilcholine canalicular transporter Mdr2 P-glycoprotein (homologous to the humanABCB4) is essential for LpX appearance, since its suppression abolishes Lp-X formation. However, the concentration of Lp-X in plasma is determined also by the degree of the cholestasis, the residual liver function, and the LCAT deficiency. The Lp-X catabolism seems to be mediated by the reticuloendothelial system and possibly the kidney. CONCLUSIONS:Lp-X might be considered a defense mechanism against the toxic effect of free cholesterol in cholestasis. The frequency of cardiovascular events in patients affected by primary biliary cholangitis, in whom the Lp-X is present in high concentration, are not increased. Further studies could now clarify the remaining open questions on the role of Lp-X in the dyslipidemia of cholestasis.
Authors: Sara Straniero; Amit Laskar; Christina Savva; Jennifer Härdfeldt; Bo Angelin; Mats Rudling Journal: J Lipid Res Date: 2020-02-21 Impact factor: 5.922
Authors: Agnieszka Ćwiklińska; Agnieszka Mickiewicz; Robert Kowalski; Barbara Kortas-Stempak; Agnieszka Kuchta; Krzysztof Mucha; Michał Makowiecki; Anna Gliwińska; Krzysztof Lewandowski; Leszek Pączek; Marcin Fijałkowski; Marcin Gruchała; Maciej Jankowski Journal: J Med Biochem Date: 2020-09-02 Impact factor: 3.402
Authors: Laura Kattah; Andrés Gómez; Sebastián Gutiérrez; Kathalina Puerto; Eiman D Moreno-Pallares; Andrés Jaramillo; Carlos O Mendivil Journal: Clin Med Insights Endocrinol Diabetes Date: 2019-09-29
Authors: Marcelo J A Amar; Lita A Freeman; Takafumi Nishida; Maureen L Sampson; Milton Pryor; Boris L Vaisman; Edward B Neufeld; Sotirios K Karathanasis; Alan T Remaley Journal: Pharmacol Res Perspect Date: 2019-12-29